Physician profile
Manoj Kumar
NPI 1104358043
$2,858.59
in general payments reported to CMS, 2019-2025
30 companies · $548 in 2025
The $548 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.74 · 2021: $236 · 2022: $898 · 2023: $353 · 2024: $799 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $627.88 | 2021-2025 | Onureg, Opdivo, Krazati |
| Seagen INC. | $373.11 | 2020-2023 | Adcetris, Tukysa |
| Novartis Pharmaceuticals Corporation | $273.84 | 2024-2025 | |
| Kite Pharma, INC. | $197.18 | 2022 | |
| Abbvie INC. | $138.10 | 2024-2025 | |
| Astellas Pharma US INC | $131.33 | 2022-2024 | Xtandi, Xospata |
| Gilead Sciences, INC. | $119.70 | 2022 | |
| Celgene Corporation | $101.30 | 2024-2025 | Reblozyl |
| Janssen Biotech, INC. | $93.64 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $91.16 | 2023-2025 | Tagrisso, Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $68.03 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $64.30 | 2022 | |
| Karyopharm Therapeutics INC. | $60.98 | 2024-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $57.43 | 2024-2025 | Alunbrig, Fruzaqla |
| Exelixis INC. | $54.05 | 2024 | Cabometyx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.01 | 2023-2025 | |
| Glaxosmithkline, LLC. | $51.96 | 2023-2025 | Ojjaara |
| Incyte Corporation | $38.85 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Array Biopharma INC | $32.69 | 2024 | Mektovi, Braftovi, Tukysa |
| Genmab U.S., INC. | $30.97 | 2024 | Epkinly |
| Daiichi Sankyo INC. | $28.20 | 2024 | Enhertu |
| Genentech USA, INC. | $27.87 | 2024 | Phesgo, Perjeta, Itovebi |
| Eisai INC. | $23.04 | 2025 | |
| Aveo Pharmaceuticals, INC. | $22.48 | 2025 | |
| Sobi, INC | $19.19 | 2024 | |
| Genzyme Corporation | $18.43 | 2024 | |
| Tempus Ai, INC | $17.79 | 2024 | |
| Jazz Pharmaceuticals INC. | $15.04 | 2024 | |
| Merck Sharp & Dohme LLC | $14.93 | 2024 | Keytruda |
| Taiho Oncology, INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.